Advertisement

Topics

Latest "Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis" News Stories

22:01 EST 12th November 2018 | BioPortfolio

Here are the most relevant search results for "Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis" found in our extensive news archives from over 250 global news sources.

More Information about Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis for you to read. Along with our medical data and news we also list Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis Clinical Trials, which are updated daily. BioPortfolio also has a large database of Thermography In Assessing Treatment Response To Golimumab In Psoriatic Arthritis Companies for you to search.

Showing "Thermography Assessing Treatment Response Golimumab Psoriatic Arthritis" News Articles 1–25 of 19,000+

Monday 12th November 2018

Cantargia AB CANTA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryCantargia AB Cantargia, a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company's product candidate CAN04 is used for the treatment of several cancers including nonsmall cell lung cancer and pancreatic cancer. It utilizes cell surface receptor as a target to develop a novel antibody based therapy for the treatment ...


Horama SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryHorama SA Horama is a biotechnology company, which develops gene therapy products based on recombinant adenoassociated virus rAAV vectors for the treatment of rare ophthalmic diseases, including retinopathies and maculopathies. Its pipeline gene replacement products include HORARPE65, developed for the treatment of retinal dystrophy caused by RPE65 gene mutations; HORAPDE6B, is designed for...

ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update

Conference call and webcast scheduled for Tuesday, November 13 at 14:30 CET/8:30 am EST  Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ($170 million) as of September 30, 2018 LYON, France and CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) --...


New Study Looks at Selumetinib for Treating Differentiated Thyroid Cancer

Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.

Aptinyx Inc APTX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryAptinyx Inc. Aptinyx, formerly Enarex Inc, is a clinicalstage biopharmaceutical company that discovers and develops novel therapies for the treatment of neurological disorders. The company's proprietary chemistry platform helps develop a pipeline of smallmolecule modulators of NmethylDaspartate NMDA receptors and improves synaptic plasticity. Many NMDA receptor modulators are under clinical...

Bioverativ Inc BIVV Medical Equipment Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryBioverativ Inc Bioverativ is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technology for the treatment of hemophilia A; and Alprolix, which comprises recombinant coagulation factor IX en...

Abiomed Touts New Study Results, Potential To Revolutionize Heart-Attack Treatment

Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company...    

CDS tool improves reader diagnosis of bladder cancer response to treatment

A decision support tool can help physicians better diagnose bladder cancer treatment response on CT, according to an Nov. 10 study published in Academic Radiology.

Dermira Inc DERM Medical Equipment Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryDermira Inc Dermira is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company's product includes QBREXZA glycopyrronium cloth, an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in pediatric and adult patien...

Mitochondria Deploy Powerful Punch Against Life-threatening Bacteria

NewsResearchers discovered that mitochondria play an important role in supporting the immune system’s response against MRSA infection.

Theravance Biopharma, Mylan get FDA approval for Yupelri

Mark Mallon, EVP, GPPS, GMA & CA, shares our commitment to #diabetes treatment innovation http://bit.ly/2OvV8zL  #AHA18pic.twitter.com/4YbTh7gcur

Mark Mallon, EVP, GPPS, GMA & CA, shares our commitment to #diabetes treatment innovation http://bit.ly/2OvV8zL  #AHA18 pic.twitter.com/4YbTh7gcur

Cellectis SA ALCLS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryCellectis SA Cellectis is a clinicalstage biopharmaceutical company that research, develop and commercialise rational genome engineering technologies. The company pioneers gene editing company, deploying core proprietary technologies to develop offtheshelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic Tcell for the treatment of cancer. Celle...

Moment Of Truth For Pacritinib And Other EU Approval Hopefuls

CTI BioPharma has had a bumpy ride with pacrotinib, its investigational treatment for patients with myelofibrosis who have thrombocytopenia. But...   

Novel Oral Paclitaxel Formulation Aims to Overcome Drawbacks of IV Version

Investigators are assessing whether Oraxol, an oral formulation of paclitaxel, will be safer and more efficacious than the widely used chemotherapy drug administered by traditional intravenous infusion.

Lurbinectedin Does Not Improve PFS in Platinum-Resistant Ovarian Cancer

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.

Sleep disorder device co Nyxoah raises $17m

The company is focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of Obstructive Sleep Apnea.

The Medicines Patent Pool Signs Licence With AbbVie to Expand Access to Key Hepatitis C Treatment, glecaprevir/pibrentasvir

SAN FRANCISCO, November 12, 2018 /PRNewswire/ -- The Medicines Patent Pool (MPP) has announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) - a World Health...

Stratifying #tuberculosis disease into minimal, moderate or severe disease may allow treatment duration to be tailored to disease severity. Minimal poor adherence is associated with poor treatment outcomes: https://go.nature.com/2B0dmpM pic.twitter.com/

Stratifying #tuberculosis disease into minimal, moderate or severe disease may allow treatment duration to be tailored to disease severity. Minimal poor adherence is associated with poor treatment outcomes: https://go.nature.com/2B0dmpM  pic.twitter.com/VYWEFXTz9R

A Major Role for a Small Organ in the Immune Response During Pregnancy

NewsThe immune system of a pregnant woman is altered during pregnancy, but not in the way previously believed.Contributed Author: 

Research Showcase launches new collaboration to accelerate translation of more predictive research models in drug discovery

Medicines Discovery Catapult and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) announce strategic collaboration to accelerate the translation of more predictive in vitro research models into new products and services Today [9 November] Medicines Discovery Catapult and the NC3Rs have announced a strategic collaboration combining research and indu...

Pulmonary Embolism: Web Tool IDs Cases Safe for Home Management

(MedPage Today) -- At-home treatment did not hurt outcomes in study

Positive 12-Month Data on BioCardia’s Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018

BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive 12 month data for the roll-in cohort of its pivotal CardiAMP™ Heart Failure Trial studying the investigational

Unique EEG Signal a Potential Depression, Anxiety Biomarker

Increased communication between the amygdala and hippocampus appear to correlate with symptoms of depression and anxiety, in findings that may have treatment implications, new research suggests. Medscape Medical News

The Center for Biosimilars® to Launch Biosimilars Stakeholders Summit

The summit will explore the role and position of biosimilar products in patient care. The Center for Biosimilars®, an online resource for emerging therapies that focuses on improving patient outcomes, will present its latest Peer Exchange titled, “Biosimilars Stakeholders Summit: Best Practices for Biosimilars Education and Promotion” on Thursday,...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks